Evidence map›Paper›PMID 34719127›Full record

ArticleBiotechnology journal2022

A BioBricks toolbox for metabolic engineering of the tetracenomycin pathway.

Jennifer T Nguyen, Kennedy K Riebschleger, Katelyn V Brown, Nina M Gorgijevska, S Eric Nybo

Open access · greenAbstract read
In one paragraph

Article in Biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jennifer T NguyenDepartment of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, Michigan, USA.
Kennedy K RiebschlegerDepartment of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, Michigan, USA.
Katelyn V BrownDepartment of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, Michigan, USA.
Nina M GorgijevskaDepartment of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, Michigan, USA.
S Eric NyboDepartment of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, Michigan, USA.ORCID https://orcid.org/0000-0001-7884-7787
Ferris State University · US

Funding

Combinatorial biosynthesis and metabolism studies of novel tetracenomycinsR15CA252830 · NCI · FERRIS STATE UNIVERSITY · PI NYBO, ERIC · 2020 to 2020
$385k
NCI NIH HHS R15 CA252830
6 · The paper itself

Abstract

BACKGROUND/GOAL/

aimThe tetracenomycins are aromatic anticancer polyketides that inhibit peptide translation via binding to the large ribosomal subunit. Here, we expressed the elloramycin biosynthetic gene cluster in the heterologous host Streptomyces coelicolor M1146 to facilitate the downstream production of tetracenomycin analogs. MAIN METHODS AND MAJOR

resultsWe developed a BioBricks genetic toolbox of genetic parts for substrate precursor engineering in S. coelicolor M1146::cos16F4iE. We cloned a series of integrating vectors based on the VWB, TG1, and SV1 integrase systems to interrogate gene expression in the chromosome. We genetically engineered three separate genetic constructs to modulate tetracenomycin biosynthesis: (1) the vhb hemoglobin from obligate aerobe Vitreoscilla stercoraria to improve oxygen utilization; (2) the accA2BE acetyl-CoA carboxylase to enhance condensation of malonyl-CoA; (3) lastly, the sco6196 acyltransferase, which is a "metabolic regulatory switch" responsible for mobilizing triacylglycerols to β-oxidation machinery for acetyl-CoA. In addition, we engineered the tcmO 8-O-methyltransferase and newly identified tcmD 12-O-methyltransferase from Amycolatopsis sp. A23 to generate tetracenomycins C and X. We also co-expressed the tcmO methyltransferase with oxygenase urdE to generate the analog 6-hydroxy-tetracenomycin C. CONCLUSIONS AND IMPLICATIONS: Altogether, this system is compatible with the BioBricks [RFC 10] cloning standard for the co-expression of multiple gene sets for metabolic engineering of Streptomyces coelicolor M1146::cos16F4iE. This production platform improves access to potent analogs, such as tetracenomycin X, and sets the stage for the production of new tetracenomycins via combinatorial biosynthesis.

Indexed as

StreptomycesStreptomyces coelicolorMetabolic EngineeringMultigene FamilyNaphthacenes5838 DNINaphthacenesBioBricksmetabolic engineeringpolyketidesStreptomycestetracenomycins

Identifiers

PMID34719127
PMCPMC8920762
OpenAlexW3208926147

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.